Yahoo Finance • 8 months ago

12 Under-the-Radar Stocks With Massive Upside for 2024

In this piece, we will take a look at the 12 under the radar stocks with massive upside for 2024. If you want to skip our overview of shareholder ownership and how shares can jump if they come 'over' the radar instead of under, then you ca... Full story

Yahoo Finance • 10 months ago

Top 11 CRISPR Stocks To Invest In

In this article, we discuss the top 11 CRISPR stocks to invest in. If you want to skip our discussion of the gene editing industry, head directly to Top 5 CRISPR Stocks To Invest In. Genome editing refers to a set of technologies enabling... Full story

Yahoo Finance • last year

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Editas Medicine, Inc. Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine’s cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -... Full story

Yahoo Finance • last year

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

Editas Medicine, Inc. All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40% All patients treated in the RUBY trial are free of vaso-occlusive events post-EDIT-301 infusion... Full story

Yahoo Finance • last year

12 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there's one t... Full story

Yahoo Finance • last year

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar Granted Vor Bio a non-exclusive li... Full story

Yahoo Finance • last year

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children’s to present EDIT-301 clinical data at ASH on Monday, December 11 CAMBRIDGE, Mass., Nov.... Full story

Yahoo Finance • last year

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m.... Full story

Yahoo Finance • last year

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced T... Full story

Yahoo Finance • last year

Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and St... Full story

Yahoo Finance • last year

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Of... Full story

Yahoo Finance • last year

Editas Medicine Announces Upcoming Investor Events

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences: 2023 Wel... Full story

Yahoo Finance • last year

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment... Full story

Yahoo Finance • 2 years ago

Editas Medicine Announces Pricing of Offering of Common Stock

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a publ... Full story

Yahoo Finance • 2 years ago

Editas Medicine Announces Offering of Common Stock

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwr... Full story

Yahoo Finance • 2 years ago

10 DNA Stocks Billionaires Are Loading Up On

In this article, we discuss 10 DNA stocks that billionaires love. If you want to skip our detailed analysis of the DNA market, head over to 5 DNA Stocks Billionaires Are Loading Up On. Genomics is the study of a complete set of DNA within... Full story

Yahoo Finance • 2 years ago

Editas Medicine Reports Inducement Grant to New Chief Financial Officer

CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer,... Full story

Yahoo Finance • 2 years ago

Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer

CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) --  Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. Lucera as Executive Vice President and Chief Financial Officer... Full story

Yahoo Finance • 2 years ago

Editas Medicine Announces First Quarter 2023 Results and Business Updates

Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) and in a Company-sponsored webinar On track to dose 20 total patients by year-end in the RUBY... Full story

Yahoo Finance • 2 years ago

Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the comprehensive data from a study of the... Full story